LH

LH

Labcorp Holdings Inc. Common Stock

$261.650+0.000 (0.000%)

السعر في الوقت الحقيقي

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$261.650

الأعلى

$261.650

الأدنى

$261.650

الحجم

0.45M

أساسيات الشركة

إحصاءات التداول

تقرير تحليل الذكاء الاصطناعي

آخر تحديث: ٢٤ مايو ٢٠٢٥
تم إنشاؤه بواسطة الذكاء الاصطناعيمصدر البيانات: Yahoo Finance, Bloomberg, SEC

LH (Labcorp Holdings Inc. Common Stock): Unpacking Recent Trends and Future Prospects

Stock Symbol: LH Generate Date: 2025-05-24 06:07:06

Let's break down what's been happening with Labcorp and what the numbers might be telling us.

The Latest Buzz: News Sentiment

The news around Labcorp lately has a pretty positive feel. We've seen several analysts from big names like Piper Sandler, Barclays, and Baird all raising their price targets for the stock. This isn't just a small bump; Piper Sandler, for instance, upped their target from $260 to $280. Barclays moved theirs from $240 to $250, and Baird went from $253 to $267.

What does this mean? Essentially, these financial experts are looking at Labcorp and seeing more value than they did before. It's a vote of confidence, suggesting they believe the stock has room to climb. On top of that, Labcorp also announced its first-quarter 2025 results, which likely played a role in these positive analyst adjustments. Good earnings often lead to brighter outlooks.

Checking the Pulse: Price Action

Looking at the last 30 days, Labcorp's stock has seen its share of ups and downs, but there's a clear pattern emerging. Back in late February and early March, the stock was hovering around the $250-$257 mark. Then, it took a noticeable dip through March and into early April, even touching lows around $212-$216.

However, things shifted significantly around April 29th. That's when Labcorp announced its Q1 results, and the stock saw a substantial jump, moving from around $221 to over $240 in a single day. Since then, it's generally been on an upward trajectory, consolidating around the $240-$250 range. The most recent close was $242.53.

Our AI model is predicting continued upward movement. It forecasts a 2.36% increase today, followed by 3.08% tomorrow, and another 3.83% the day after. If these predictions hold, we're looking at the stock potentially reaching around $260.51 in the near term. This aligns with the recent positive momentum and the analyst upgrades.

What's the Outlook and What Could You Do?

Putting it all together, the current situation for Labcorp seems to lean positive. The consistent analyst upgrades, coupled with the stock's rebound after its Q1 earnings, paint a picture of renewed optimism. The AI's high confidence in an upward trend further supports this.

Given this, the apparent near-term leaning suggests a potential 'buy' or 'accumulate' window for investors.

  • Potential Entry Consideration: If you're thinking about getting in, the current price around $242.53 looks interesting, especially considering the AI's prediction of an upward trend starting today. The AI model even suggests entry points around $243.24 to $244.23. This area seems to be a good spot where the stock has found support recently.

  • Potential Exit/Stop-Loss Consideration: For managing risk, a stop-loss around $217.75 could be considered. This level is well below recent lows and would help limit potential losses if the positive trend doesn't materialize. On the upside, if the stock continues its climb as predicted, a take-profit target around $246.79, or even higher towards the AI's projected $260.51, could be on the table. Remember, the analysts have targets as high as $280, so there might be more room to run if the broader market agrees.

A Bit About Labcorp

It's worth remembering that Labcorp Holdings Inc. is a major player in the Diagnostics & Research sector within Healthcare. They provide a huge range of laboratory services, from basic blood tests to specialized genetic testing and drug development support. With 60,900 full-time employees, they're a significant entity. Their business is directly tied to healthcare demand, so factors affecting patient visits, medical testing, and pharmaceutical research can all impact their performance. The recent positive news suggests these areas are looking good for them right now.


Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Investing in stocks involves risks, and you could lose money. Always conduct your own thorough research and consult with a qualified financial professional before making any investment decisions.

أخبار ذات صلة

GlobeNewswire

Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp

PITTSBURGH, June 12, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery, announced today the company has successfully developed 3D organoid models exclusively for

عرض المزيد
Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp
Analyst Upgrades

Morgan Stanley Maintains Overweight on Labcorp Hldgs, Raises Price Target to $283

Morgan Stanley analyst Ricky Goldwasser maintains Labcorp Hldgs with a Overweight and raises the price target from $270 to $283.

عرض المزيد
Morgan Stanley Maintains Overweight on Labcorp Hldgs, Raises Price Target to $283

تنبؤ الذكاء الاصطناعيBeta

توصية الذكاء الاصطناعي

صعودي

تم التحديث في: ١٢ يونيو ٢٠٢٥، ٠٩:٤٢ م

هبوطيمحايدصعودي

76.0% الثقة

المخاطر والتداول

مستوى المخاطرة3/5
مخاطرة متوسطة
مناسب لـ
متحفظ
دليل التداول

نقطة الدخول

$260.16

جني الأرباح

$272.57

وقف الخسارة

$234.03

العوامل الرئيسية

مؤشر PDI 5.0 فوق مؤشر MDI 3.9 مع مؤشر ADX 16.9، مما يشير إلى اتجاه صعودي
السعر الحالي قريب جدًا من مستوى الدعم (259.37 دولار)، مما يشير إلى فرصة شراء قوية
حجم التداول 8.6 ضعف المتوسط (6,812)، مما يشير إلى ضغط شراء قوي للغاية
مؤشر MACD -0.1748 فوق خط الإشارة -0.2549، مما يشير إلى تقاطع صعودي

ابق على اطلاع

تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.